A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube

发表于 2026-8-2 19:00:20

期刊：Gynecologic Oncology

文献作者：Rebecca Kristeleit; Irina Davidenko; Vadim Shirinkin; Fatima El-Khouly; Igor Bondarenko; Michael J. Goodheart; Vera Gorbunova; Carol A. Penning; Jack G. Shi; Xiangdong Liu; Robert C. Newton; Yufan Zhao; Janet Maleski; Lance Leopold; Russell J. Schilder

出版日期：2017-9-

DOI号：10.1016/j.ygyno.2017.07.005

下载链接：https://www.sciencedirect.com/science/article/pii/S0090825817310223/pdf

文献链接：https://doi.org/10.1016/j.ygyno.2017.07.005

当前文献来源于 <span style="color: #0E8ED8">Elsevier BV</span>。

备注信息：

发表于 2026-8-2 19:00:21

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube 一键复制